0001 GMT - Integral Diagnostics gets a new bull at Bell Potter in anticipation of the enhanced scale offered by the imaging provider's merger with Capitol Health. Analyst Martyn Jacobs tells clients in a note that the combined Integral-Capitol business will become Australia's third-largest imaging provider, creating operating leverage and opportunities in telehealth. He says that regulatory changes could allow the group to extend operating hours, generating an additional A$11 million in fiscal 2026 revenue. Bell Potter initiates coverage with a buy rating and A$3.87 target price on the stock, which is up 4.0% at A$3.16. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 04, 2024 19:01 ET (00:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。